Acadia Pharmaceuticals reported $40.36M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 40.36M 68.31M Sep/2026
ALKERMES USD 261.1M 37.86M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Biogen USD 2.22B 159.9M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Bristol-Myers Squibb USD 2.7B 33M Sep/2026
Cara Therapeutics USD 900K 0 Mar/2025
Corcept Therapeutics USD 11.91M 1.28M Sep/2026
Cytokinetics USD 807K 427K Sep/2026
Eisai JPY 272.61B 15.06B Sep/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
Incyte USD 134.25M 21.71M Sep/2026
J&J USD 15.38B 233M Sep/2026
Moderna USD 313M 33M Sep/2026
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
PTC Therapeutics USD 109.33M 17.98M Sep/2026
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026